| Bioactivity | PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC50 values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders and psychiatric disorders[1]. | ||||||||||||
| Invitro | PDE1 enzymes are expressed in the central nervous system (CNS), making this gene family an attractive source of new targets for the treatment of psychiatric and neurodegenerative disorders[1]. | ||||||||||||
| Name | PDE1-IN-2 | ||||||||||||
| CAS | 1904611-63-7 | ||||||||||||
| Formula | C16H21BrN4O2 | ||||||||||||
| Molar Mass | 381.27 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Jan Kehler, et al. Triazolopyrazinones as pde1 inhibitors. WO2016055618A1. |
PDE1-IN-2
CAS: 1904611-63-7 F: C16H21BrN4O2 W: 381.27
PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC50 values of 6 nM, 140
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.